Bệnh Bạch Cầu Tế Bào Phôi

Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy

By MedXY 05/29/2026

A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for immune recovery.

Hematology-Oncology news Oncology

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY 05/27/2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

AI Hematology-Oncology news

Choosing a Stem Cell Donor: Why Age Matters More in Some Transplants Than Others

By MedXY 05/21/2026

A major 2026 study suggests donor age affects survival differently in haploidentical and matched unrelated stem cell transplants, offering a more practical framework for choosing the best donor.

Hematology-Oncology news

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

By MedXY 03/29/2026

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for specialized flow cytometry monitoring during menin inhibitor therapy.